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Background: Patients with Estrogen Receptor a-positive (ERþ) Inflammatory Breast Cancer
(IBC) are less responsive to endocrine therapy compared with ERþ non-IBC (nIBC) pa-
tients. The study of ERþ IBC samples might reveal biomarkers for endocrine resistant
breast cancer.
Materials & methods: Gene expression profiles of ERþ samples from 201 patients were
explored for genes that discriminated between IBC and nIBC. Classifier genes were applied
onto clinically annotated expression data from 947 patients with ERþ breast cancer and
validated with RT-qPCR for 231 patients treated with first-line tamoxifen. Relationships
with metastasis-free survival (MFS) and progression-free survival (PFS) following adjuvant
and first-line endocrine treatment, respectively, were investigated using Cox regression
analysis.
Results: A metagene of six genes including the genes encoding for 4-aminobutyrate
aminotransferase (ABAT ) and Stanniocalcin-2 (STC2) were identified to distinguish 22ical Oncology, Erasmus MC Cancer Institute, Room Be401, Wytemaweg 80, P.O. Box 2040,
31 107044373; fax: þ31 107044377.
smc.nl (M.P.H.M. Jansen).
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M O L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 2 1 8e1 2 3 3 1219ABATSTC2ERþ IBC from 43 ERþ nIBC patients and remained discriminatory in an independent series
of 136 patients. The metagene and two genes were not prognostic in 517 (neo)adjuvant
untreated lymph node-negative ERþ nIBC breast cancer patients. Only ABAT was related to
outcome in 250 patients treated with adjuvant tamoxifen. Three independent series of in
total 411 patients with advanced disease showed increased metagene scores and decreased
expression of ABAT and STC2 to be correlated with poor first-line endocrine therapy
outcome. The biomarkers remained predictive for first-line tamoxifen treatment outcome
in multivariate analysis including traditional factors or published signatures. In an
exploratory analysis, ABAT and STC2 protein expression levels had no relation with PFS
after first-line tamoxifen.
Conclusions: This study utilized ERþ IBC to identify a metagene including ABAT and STC2 as
predictive biomarkers for endocrine therapy resistance.
ª 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction specific expression profile harbors the molecular traits ofBreast cancer is the most prevalent form of cancer in women
in the United States and Europe (Torres-Arzayus et al., 2010).
The majority of patients with breast cancer bear tumors
expressing detectable levels of the Estrogen Receptor (ER).
For these patients, targeted therapies are available including
strategies directed at the receptor itself, such as tamoxifen
and fulvestrant. In addition, estrogen deprivation offers
another therapeutic strategy that can be achieved by ovarian
ablation, or LHRH analogs, in the premenopausal patient, or
with aromatase inhibitors (AIs) in the postmenopausal
setting. These therapies are highly effective; adjuvant endo-
crine therapy has been shown to reduce mortality from ERþ
breast cancer to the same degree as adjuvant chemotherapy
(Early Breast Cancer Trialists’ Collaborative, G, 2005). Unfortu-
nately, part of the patients with ERþ breast cancer show de
novo resistance to endocrine therapy, whereas others initially
benefit but ultimately relapse due to acquired endocrine resis-
tance (Leary et al., 2010). Predicting, modulating and/or
restoring endocrine responsiveness remain important clinical
priorities for which molecular targets are urgently needed.
Inflammatory breast cancer (IBC) is a rare (w5%) but
aggressive form of locally advanced breast cancer. At time of
diagnosis, virtually all patients with IBC have lymph nodeme-
tastases and 1/3 of the patients havemetastases in distant or-
gans. As a consequence, the prognosis for patients with IBC is
dismal (Dawood et al., 2011; Dirix et al., 2006). Analysis of the
Surveillance, Epidemiology and End Results (SEER)-database
revealed that IBC is characterized by atypical clinicopatholog-
ical features (Dawood et al., 2011), including frequent absence
of ER protein expression (Hance et al., 2005). Our research
group and others have shown that this IBC-specific clinico-
pathological profile is corroborated at the molecular level by
a distinct gene expression profile (Bertucci et al., 2004; Van
Laere et al., 2007a; Van Laere et al., 2005). Exploration of this
gene expression profile led to the discovery of pronounced
activation of the transcription factor NFkB in IBC (Lerebours
et al., 2008; Van Laere et al., 2006) and more recently to the
observation that TGFb-signaling is repressed (Van Laere
et al., 2008). Furthermore, we demonstrated that the IBC-aggressive tumor cell behavior in general (Van Laere et al.,
2008), including stem cell biology (Van Laere et al., 2010). As
such, we consider IBC, although occurring rarely, as a suitable
example to elucidate mechanisms responsible for tumor cell
dissemination, metastasis and drug resistance in breast can-
cer in general.
The majority (depending on the reference up to 66%) of pa-
tients with IBC lack ER protein expression, but ERþ tumor
samples from patients with IBC exist. Clinically, patients
with ERþ IBC are less responsive to endocrine treatment as
compared to patients with other forms of ERþ breast cancer.
In light of molecular heterogeneity and our previous results,
we reasoned that studying ERþ IBC focusing on endocrine
treatment response might provide new insights into molecu-
lar resistance mechanisms of endocrine therapy. In the cur-
rent study, we evaluated expression profiles from patients
with ERþ IBC and nIBC. The purpose of this study was 1) to
identify differentially expressed genes between IBC and
nIBC, 2) assess their accuracy to predict ERþ IBC, and 3) to
define their relationship with endocrine therapy response in
clinical samples. Discriminatory genes were identified by
gene expression arrays, of which two genes remained deregu-
lated in an independent series of ERþ samples between pa-
tients with and without IBC. When applied onto clinically
annotated expression series from patients with ERþ breast
cancer treated with endocrine therapy either in the adjuvant
or advanced setting, decreased expression of these two genes
were linked with poor responsiveness to endocrine therapy.
These two genes when validated with quantitative real-time
PCR for mRNA expression and with immunohistochemistry
for protein expression, demonstrated predictive value only
at the mRNA level.2. Materials and methods
2.1. Study design and patient samples
The present study describes a retrospective analysis per-
formed in accordance with the Code of Conduct of the
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Belgium and France, and is reported following the REMARK
recommendations (McShane et al., 2006). The local medical
ethics committees have approved the study. Follow-up, tumor
staging, and response to therapy was defined by standard In-
ternational Union Against Cancer (Geneva, Switzerland) clas-
sification criteria (Hayward et al., 1978). Samples were
recruited from the Translational Cancer Research Unit
(TCRU, Antwerp, Belgium), the Institut Poali-Calmettes (IPC,
Marseille France), the Erasmus Medical Center (EMC, Rotter-
dam, the Netherlands) and the Netherlands Cancer Institute
(NKI, Amsterdam, the Netherlands). The ER-status of the tu-
mors was established by immunohistochemistry (10% posi-
tive tumor cells) or EIA (10 fmol/mg protein) and together
with additional clinicopathological characteristics have been
described before for each of the series (Bekhouche et al.,
2011; Desmedt et al., 2007; Jansen et al., 2013; Kok et al.,
2009; Loi et al., 2008; Reijm et al., 2014; Schmidt et al., 2008;
Van der Auwera et al., 2010; Van Laere et al., 2007b; Wang
et al., 2005).
The mRNA-datasets used in this study are presented in
Table 1 and includes ERþ IBC-subsets (IeII), endocrine treated
subsets (IIIeVI), and untreated lymph node-negative (LNN)
patients (VIIeIX).
The discovery and test phase incorporated 2 patient series
with ERþ IBC: a) a discovery series (I) of 65 samples from pa-
tients with and without ERþ IBC retrieved from the TCRU (E-
MTAB-1006) and b) an independent test series (II) of samples
from 136 patients with and without ERþ IBC that received
adjuvant treatment, retrieved from IPC. Samples from pa-
tients with ERþ IBC in series I (N ¼ 22) and series II (N ¼ 39)
were selected by strictly adhering to the consensus diagnostic
criteria (Dawood et al., 2010).
To evaluate discovered genes for their relationship with
endocrine treatment outcome, 4 additional data sets (IIIeVI)
were incorporated of patients with ERþ breast cancer treated
with endocrine therapy for primary and advanced disease: 3
data sets (IVeVI) of 411 metastatic breast cancer patients in
total from EMC, NKI and TRCU; and 1 data set with primary
breast cancers of 250 patients (III). The data set of 411 patients
with advanced ERþ breast cancer treated with first-line ther-
apy contained three subsets, one of 96 patients treated withTable 1 eDatasets. Detailed information on the datasets used in this stud
information about its study subject (IBC, treatment outcome, clinical outco
to the array-platform.
Information of datasets used in this study
Series Analysis Subset Reference
I IBC Discovery Van Laere et al.
II Validation Bertucci et al.
III Treatment Outcome Tamoxifen Adjuvant Loi et al.
IV Tamoxifen Advanced Kok et al.
V Aromatase Inhibitors Jansen et al. (20
VI Tamoxifen Advanced Jansen et al. (20
VII Clinical Outcome LNN ERþ, untreated Wang et al.
VIII LNN ERþ, untreated Desmedt et al.
IX LNN ERþ, untreated Schmidt et al.tamoxifen (IV) and one of 84 patients treated with aromatase
inhibitors (AIs) (V), and one of 231 patients treated with
tamoxifen and profiled using RT-qPCR for dedicated genes
(VI). The RT-qPCR data set was used as an independent valida-
tion series for the genome-wide expression series. All samples
in these cohorts were classified according to the Recurrence
Score (RS) (24), the Genomic Grade Index (GGI) (25). For each
of these patient series tumor size and histological grade
were recorded, in addition to age and menopausal status at
start of therapy, dominant site of relapse and disease-free in-
terval for the RT-qPCR data set. To assess the prognostic value
of the discovered genes, we incorporated also 3 series (VII-IX)
of ERþ tumors from 517 LNN breast cancer patients, who did
not receive any type of adjuvant systemic therapy. Details
regarding the application of the above classifiers are provided
in the Supplementary data file, Tables A.1 and A.2.
The discovered predictive genes were also evaluated for
their protein expression pattern in a tissue microarray
including cores of ER-positive primary tumor specimens
from a cohort of advanced breast cancer patients who have
been treated with first-line tamoxifen previously described
(Reijm et al., 2014). A subset of 110 ER-positive tumors were
explored for their protein staining, i.e. the number of positive
cells and the staining intensity, and a staining IHC-score was
calculated to evaluate the relationship between IHC-score and
progression-free survival.2.2. Methods
2.2.1. RNA isolation and (genome-wide) expression profiling
RNA isolation for the samples retrieved from each of the
participating centers (TCRU, EMC, NKI and IPC) and quality
control was done as described before (Bekhouche et al., 2011;
Jansen et al., 2005, 2013; Kok et al., 2009; Van Laere et al.,
2007a). Genome-wide expression profiles were available
from Affymetrix HGU133A or HGU133plus2 platforms (IeIII,
VIIeIX) and 44k mRNA oligoarrays of Agilent Technologies
(IVeV).
Expression analyses were verified by RT-qPCR (series VI)
andwere performed for the “IBC-like” genes (i.e.ABAT,ADAM-
DEC1, CLEC7A, ETS1, ITK and STC2) to discriminate betweeny. The datasets are numbered as series I to IX and the subset provides
me). For each dataset the author and array reference are presented next
GEO/ArrayExpress Platform Total number of cases
E-MTAB-1006 Affymetrix 65
NA Affymetrix 136
GSE6532 Affymetrix 250
NA Agilent 96
13) GSE41994 Agilent 84
07) NA qRT-PCR 231
GSE2034 Affymetrix 221
GSE7390 Affymetrix 134
GSE11121 Affymetrix 162
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BAG1, BCL2, BIRC5, CCNB1, CD68, CTSL2, ERBB2, ESR1, GRB7,
GSTM1, MKI67, MMP11, MYBL2, PGR and SCUBE2) and for a
panel of reference genes (i.e. HMBS, HPRT1, TBP and B2M ).
Assay details are provided in Supplementary Table A.1. The
cDNA synthesis, quantification and the methodology to
ensure PCR specificity have been described previously
(Sieuwerts et al., 2005; van Agthoven et al., 2009). RT-qPCR
was performed in aMx3000P Real-Time PCR System (Agilent,
Amsterdam, The Netherlands) using the TaqMan-based gene
expression assays from Applied Biosystems/Life Technologies
and SYBR-based intron-spanning forward and reverse primer
combinations for the other genes. Levels of the target genes,
expressed relative to the reference genes were quantified as
follows: mRNA target ¼ 2(mean Ct reference genesmean Ct target
genes).
Expression levels of each series (Supplementary Table A.2)
were normalized and subsequently harmonized for cross-
platform evaluation and robust regression analyses. To
accomplish harmonization of series, Hampel’S M-Estimators
were calculated in SPSS (version 20) for all series and applied
to establish the harmonization factor for the genes in each se-
ries when using series I as reference (Supplementary Table
A.3).
2.2.2. Comparative analysis or ERþ IBC and nIBC expression
profiles
Global differences in gene expression between samples from
patients with and without ERþ IBC in the discovery series
were analyzed using the global test (Goeman et al., 2004) and
Principal Component Analysis (PCA). Using the PAM50-
algorithm, each sample in the discovery series was classified
according to the molecular subtypes, ER activity, and Risk-
Of-Relapse (ROR) models based on the molecular subtypes
alone (ROR-S) or in combination with cell proliferation (ROR-
P), as described before (Ellis et al., 2011). In addition, the Recur-
rence Score (RS) (Paik et al., 2004) and the HOXB13/IL17RB gene
expression ratio (Jansen et al., 2007; Ma et al., 2006) were
calculated.
2.2.3. Biomarker discovery analysis
We performed Prediction Analysis of Microarrays (PAM)
(Tibshirani et al., 2002) to identify a series of biomarkers able
to discriminate ERþ IBC from ERþ nIBC samples. The discov-
ery series were randomly divided into training sets of 40 sam-
ples and test sets of 25 samples to obtain 10 gene signatures,
which were compared to identify common classifiers. In total
six classifier genes were shared between these 10 gene signa-
tures, i.e. ABAT, ADAMDEC1, CLEC7A, ETS1, ITK and STC2. PCA
was performed onto the ERþ IBC discovery and validation se-
ries to evaluate the discriminatory performance of all genes
and of the six common classifier genes together. Mutual rela-
tionships between these common classifier genes and ERwere
investigated using the Ingenuity Pathway Analysis (IPA)
software.
2.2.4. Construction of an ERþ IBC-like metagene
The thus identified six genesABAT, ADAMDEC1, CLEC7A, ETS1,
ITK and STC2 were combined into an ERþ IBC-like metagene.
The regression coefficients of each of the genes obtainedwithin the discovery series were used to calculate a score for
the metagene in all other series. This metagene score was
evaluated as biomarker representing the signature of above
six genes.
2.2.5. Diagnostic evaluation of biomarkers and classifiers
The IBC discovery and test sets (series I & II) were used to
assess the predictive potential of the biomarkers to identify
IBC and nIBC. The biomarkers were evaluated as continuous
variables with Receiver Operator Characteristic (ROC) ana-
lyses using the STATA statistical package. The ROC analyses
were performed to define Area Under Curves (AUC) and assess
the discriminatory potential of the biomarkers. Next, ROC an-
alyses were used to select cutoffs with optimal sensitivity and
specificity. These cutoffs generated dichotomized biomarkers
which were subsequently explored as classifiers using distri-
bution dot-plots created in STATA and evaluated for their
diagnostic effectiveness by SISA (http://www.quantitative-
skills.com/sisa/). The distribution dot-plots illustrated the per-
formance and the number of false positives/negatives when
applying the cutoffs. The SISA tool established for the classi-
fiers their accuracy, sensitivity, specificity and Youden’s Index
of the predictions.
2.2.6. Survival analysis of biomarkers and classifiers
The biomarkers were evaluated for their relationship with
survival using Cox regression analyses in two ways: as a
continuous variable or dichotomized to a threshold as classi-
fier to distinguish “IBC-like” and “nIBC-like”. For the assess-
ment of the relationship with first-line therapy outcome in
advanced disease, Progression-Free Survival (PFS), defined as
the time elapsed between initiation of endocrine therapy
and the first detection of disease progression, was considered
as endpoint. PFS was censored at 36 months. For the assess-
ment of the relationship with prognosis and adjuvant therapy
in early disease, Metastasis-Free Survival (MFS) was used as
endpoint and defined as the time elapsed between the date
of diagnosis and the date of distant metastatic relapse. Multi-
variate Cox regression analyses were performed on each of
the endocrine treated advanced disease subsets for PFS (series
IVeVI). The models included the biomarkers as continuous
variable on the one hand and the published signatures for
the Recurrence Score or the GGI on the other hand. Additional
multivariate analyses were performed with the base model of
clinic-pathological factors including age and menopausal sta-
tus at start of therapy, dominant site of relapse, disease free
interval (DFI), and the mRNA expression levels of ER (ESR1),
PR (PGR), and HER2 (ERBB2). All data computations were
done with the STATA statistical package version 12.0. All
P-values are two-sided and P < 0.05 was considered statisti-
cally significant.
2.2.7. Tissue microarrays and immunohistological and
evaluation
Tissue microarrays (TMAs) of formalin-fixed, paraffin-
embedded primary breast tumor specimens were prepared
and immunohistochemically stained according to the proce-
dures described previously (Reijm et al., 2014). The staining
was performedwith the primarymonoclonal antibody against
ABAT (HPA041690) and STC2 (HPA045372; Atlas Antibodies AB,
Figure 1 e IBC discriminatory genes. Evaluation of IBC and nIBC in the discovery series I (Figure 1AeB) and of ERD IBC discriminatory genes
(ABAT, ADAMDEC1, CLEC7A, ETS1, ITK, STC2) (Figure 1C). Figure 1A illustrates the Principle Component Analyses of the tumor samples by
their gene expression profiles. Red dots denote ERD IBC samples, blue dots denote ERD nIBC samples. The centroids for both tumor
phenotypes are indicated in black and labeled respectively “Centroid IBC” and “Centroid nIBC”. PCA for the common 6 classifier genes showed
an expected segregation of ERD samples from patients with and without IBC on the 2D scatter plot representation of the 1st (X-axis) and the 2nd
(Y-axis) principal component. Class label permutation analyses (applying 100 class label permutations) demonstrated that the centroids of the
ERD samples from patients with and without IBC are significantly segregated (Observed Euclidean distance[ 4.555, average expected Euclidean
distance [ 0.890; P< 0.010). Figure 1B presents the results on PAM50 analyses, Recurrence score, and HOXB13/IL17RB. For PAM50, the
percentage Luminal A-type tumors in IBC and nIBC is provided in addition to the ROR-S, ROR-P and ER activity scores. The ER activity score
ranges from negative to positive, with negative values indicating repressed ER activity. In addition, the RS and the HOXB13/IL17RB gene
expression ratio are provided for both tumor types. The reported P-values result from the comparison of the IBC and nIBC groups with respect to
these variables. Figure 1C depicts the network obtained for the 6 IBC discriminatory genes together with the estrogen receptor-a (ESR1) when
evaluated with Ingenuity Pathway Analyses. This exploratory analysis revealed interactions with hormone receptor signaling, inflammation, cell
survival, epidermal growth factor signaling, stem cell signaling and TGFb signaling, indicating a potential involvement for each of these biological
features in endocrine resistance. The molecules are color-coded red if the corresponding gene is overexpressed in ERD IBC samples and green if
the corresponding gene is repressed in ERD IBC samples. Uncolored nodes are added by the software. Solid lines signify direct geneegene
interactions, whereas broken lines represent indirect relationships that may require secondary effectors not depicted in the network. All
connections are supported by at least one published report or from canonical information stored in the Ingenuity Pathway Knowledge Base.
Table 2 e ERD IBC discriminatory genes. The expression levels in
IBC and nIBC, significance and regression coefficients for the genes
identified in the biomarker discovery analysis.
ERþ IBC-Metagene
Median expression level
Genes nIBC
(N ¼ 43)
IBC
(N ¼ 22)
P-value Regression
coefficient
ABAT 10.63 8.64 9.19E-08 0.295
ADAMDEC1 6.26 9.07 1.31E-03 0.566
CLEC7A 7.24 8.12 9.55E-03 0.270
ETS1 4.09 4.99 7.09E-05 0.112
ITK 5.27 7.09 2.49E-04 0.332
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(1:100 dilution) after 20 min antigen retrieval at pH6.0. Subse-
quently, the TMA-slides were incubated with a secondary
antibody and staining was visualized using diaminobenzidine
(DAB). ABAT and STC2 protein staining was scored for quan-
tity and intensity. Stainingwas grouped into standardized cat-
egories for the percentage of staining positive cells (0%,
1e20%, 21e50%, 51e75%, or 76e100% of positive cells) and
for staining intensity (negative, weak, moderate, strong). Sub-
sequently, the scores for quantity and intensity were multi-
plied to generate a staining IHC-score. Based on the IHC-
score, a specimen was classified as negative or positive for
ABAT and STC2 protein expression.STC2 10.8 7.64 1.70E-04 0.6303. Results
3.1. Comparative analysis of ERþ IBC and nIBC
expression profiles
Using global test analysis and PCA,we observed that ERþ sam-
ples from patients with and without IBC exhibited significant
differences in their expression profiles that led to segregation
of IBC and nIBC samples in the PCA plot of the discovery series
(Figure 1A). Evaluation of the Recurrence Score, the HOXB13/
IL17RB expression ratio and PAM50-derived scores for molec-
ular subtypes, ER activity, risk of relapse models (ROR-S and
ROR-P), indicated decreased ER signaling and sensitivity to
endocrine treatment for ERþ samples from IBCs compared
to those of nIBCs (Figure 1B).
3.2. Biomarker discovery analysis
As shown above, ERþ IBC samples exhibited molecular char-
acteristics of resistance to endocrine therapy, making their
gene expression profiles a potential source for biomarker dis-
covery. Using PAM on 10 alternatively composed training sets
of 40 randomly selected ERþ samples from the discovery set
(series I), we generated 10 distinct gene signatures distin-
guishing IBC from nIBC samples. Application of these gene
signatures onto corresponding series of the 25 left-out sam-
ples revealed an average sensitivity of 89% (range 71%e
100%), specificity of 80% (range 67%e100%) and test error
rate of 18% (range 0%e28%). These 10 gene signatures had 6
overlapping genes: ABAT, ADAMDEC1, CLEC7A, ETS1, ITK1
and STC2. Relative to nIBC, ABAT and STC2 expression levels
were decreased in IBC whereas the levels of the remaining 4
genes were increased (Table 2 and Figure 2). Exploratory IPA
analysis was performed to investigate mutual relationships
between the 6 classifier genes and ER (Figure 1C) and sug-
gested their potential involvement in endocrine therapy
resistance.
3.3. Diagnostic effectiveness of biomarkers and
classifiers
Next, these six genes were evaluated for their potential to
distinguish IBC from nIBC in an independent subset of pa-
tients with and without IBC (series II). Only the AUCs for the
metagene score, ABAT, and STC2 were discriminatory andcomparable in both the discovery and test cohort (Figure 2).
The ROC AUCs of these three biomarkers were further
explored to establish optimal classifier cutoffs. Distribution
dot-plots in the discovery cohort were used to verify the ERþ
IBC classification thresholds, whichwere set for themetagene
score at 0.0 and for both ABAT and STC2 at  10.0 (Figure 3A,
C and E). The classifiers, however, exhibited moderate diag-
nostic effectiveness with regard to ERþ IBC prediction, since
only a maximum of 64% accuracy was achieved within the
test (Figure 3B, D and F).
3.4. Biomarkers in early disease: prognosis and
adjuvant tamoxifen
Themetagene score, ABAT, and STC2were subsequently eval-
uated as continuous variable for their relationship with MFS
with regard to prognosis and outcome after adjuvant tamox-
ifen (Table 3). The prognostic value was determined on three
series of in total 517 (neo)adjuvant systemic treatment na€ıve
patients with ERþ LNN breast cancer (series VIIeIX). None of
the biomarkers, assessed by microarrays, were prognostic
when evaluated for all 517 patients. The biomarkers were
also evaluated in 250 ERþ patients treated with adjuvant
tamoxifen (series III). Decreased expression of ABAT
(HR ¼ 0.73; 95% CI ¼ 0.61e0.87; P ¼ 0.001) showed a significant
correlationwith poorMFS in these tamoxifen treated patients,
whereas STC2 and the metagene score had no association
with MFS after tamoxifen.
3.5. Biomarkers and first-line endocrine therapy for
advanced disease
The metagene score, ABAT, and STC2 were also evaluated for
their relation with PFS on microarray based series of patients
with advanced disease treated with first-line tamoxifen (IV,
N ¼ 96) or aromatase inhibitors (V, N ¼ 84), and validated
with RT-qPCR on an independent series of patients treated
with first-line tamoxifen (VI, N ¼ 231). As continuous vari-
ables, increased metagene scores and decreased expression
of ABAT and STC2 were correlated with poor treatment
outcome in all three series of patients, except for STC2 in se-
ries IV (Table 3). As classifiers, apart from STC2 in series IV,
Figure 2 e Receiver Operator Characteristics (ROC) Analyses. The ROC-analyses generate Area Under Curve (AUC) values presented in
Figure 2A as measure for the discriminatory potential of the individual genes to predict IBCs and nIBCs correctly within the test (series II)
compared to the discovery (series I). Factors with AUC (or their intervals) value 0.5 are not informative. The results show as illustrated with ROC
plots in Figure 2B that AUCs for only the metagene, ABAT and STC2 are discriminatory and comparable for the discovery and test.
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Figure 3 e Dot-plots and diagnostic effectiveness. This figure represents dot-plots and the diagnostic performance of the biomarkers in the
discovery and test series for IBC and nIBC (series I and II). The metagene scores and expression levels of ABAT and STC2 measured in the
discovery (series I) were evaluated in dot-plots to explore the defined thresholds that classify samples as IBC-like or nIBC-like. The diagnostic
effectiveness of the biomarker IBC classification were evaluated in the independent test (series II).
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Table 3 e Biomarkers and outcome. This table provides the results of the univariate Cox regression analyses performed for MFS and PFS to
determine the prognostic and predictive value of the metagene, ABAT and STC2 in the different patient series.
Clinical setting Series N outcomea Biomarkers as continuous variable:
Metagene score ABAT STC2
HR (95%CI)b P HR (95%CI) P HR (95%CI) P
Early Disease
Prognosis VIIeIX 517 MFS 0.99 (0.92e1.08) 0.967 0.93 (0.82e1.06) 0.298 1.01 (0.92e1.11) 0.867
Adjuvant tamoxifen III 250 MFS 1.09 (0.99e1.20) 0.084 0.73 (0.61e0.87) 0.001 0.93 (0.83e1.04) 0.216
Advanced Disease
First-line tamoxifen IV 96 PFS 1.13 (1.03e1.25) 0.012 0.80 (0.69e0.93) 0.004 0.90 (0.79e1.03) 0.117
First-line aromatase inhibitors V 84 PFS 1.28 (1.13e1.45) <0.001 0.74 (0.60e0.91) 0.004 0.76 (0.66e0.88) <0.001
First-line tamoxifen VI 231 PFS 1.09 (1.04e1.14) <0.001 0.85 (0.80e0.92) <0.001 0.93 (0.88e0.98) 0.004
a Outcome defined by metastasis free survival (MFS) or by progression free survival (PFS).
b Hazard Ratio (HR) and its 95% confidence interval (CI) for MFS in early disease and PFS in advanced disease.
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for all series in the KaplaneMeier survival analyses (Figure 4).
3.6. Biomarkers and published signatures
The biomarkers were compared for their relation with PFS in
advanced disease (series IV, V, VI) with published signatures
for Recurrence Score and GGI (Table 4). When compared to
Recurrence Score and GGI only ABAT remained significantly
associated with PFS in all series (except for GGI in series V).
In contrast, the metagene score and STC2 were only indepen-
dent fromRecurrence Score and GGI in AI-treated patients (se-
ries V). In summary, especially ABAT expression levels were
independently associated with PFS when compared to pub-
lished signatures separately and validated with RT-qPCR.
3.7. Biomarkers and clinicopathological predictors
Multivariate analyses were performed by adding the bio-
markers separately to a base model of traditional clinicopath-
ological factors for endocrine therapy in advanced disease
(Table 5). The model included age, menopausal status, domi-
nant site of relapse, disease-free interval and mRNA expres-
sion levels for ESR1, PGR, and ERBB2. These multivariate
analyses showed that low ABAT levels were significantly
related with poor PFS in the series of 96 patients treated
with tamoxifen (series IV (HR ¼ 0.78, P ¼ 0.027)), whereas
high metagene scores (HR ¼ 1.24, P ¼ 0.005) and low STC2
levels (HR ¼ 0.79, P ¼ 0.011) were associated with poor PFS in
the series of 84 patients treatedwith AI (seriesV). All three bio-
markers were independently related with PFS in the RT-qPCR
validation series of 231 patients treated with tamoxifen
(series VI).
3.8. Biomarkers and protein expression
In an exploratory study, ABAT and STC2 protein expression
were examined in 110 ER-positive primary breast cancer spec-
imens (Figure 5A). Evaluation of quantity and intensity sepa-
rately showed for both proteins no significant relationships
with PFS (Supplementary Figure 1). The quantity and intensity
scores were multiplied to generate an IHC-score for thestaining and classified 77 specimens (69%) as ABAT-positive
and 78 specimens (70%) as STC2-positive (Figure 5B). These
dichotomized IHC-scores were not related with PFS, i.e. not
for ABAT (HR ¼ 0.79; 95% CI ¼ 0.51e1.23; P ¼ 0.30) and not
for STC2 (HR ¼ 0.93; 95% CI ¼ 0.60e1.44; P ¼ 0.74).4. Discussion
Inflammatory breast cancer is a rare (w5%) but highly aggres-
sive form of locally advanced breast cancer with an elevated
invasive and metastatic potential. It is characterized by clin-
ical and pathological characteristics atypical for breast cancer
in general, amongst others a low frequency of ER positivity. In
the past, we showed that the molecular portrait of IBC indeed
contained fingerprints of aggressive tumor cell behavior in
breast cancer in general (Van Laere et al., 2008). Patients
with IBC bearing ER expressing tumor cells constitute approx-
imately 30% of all IBC cases and endocrine treatment in these
patients is observed to be poorly effective. The molecular pro-
file of samples from patients with ERþ IBC could provide addi-
tional hints towards unraveling the molecular biology
associated with resistance to endocrine treatment. In this
study, we demonstrate that, at least at the molecular level,
ERþ IBC is characterized by features associated with endo-
crine resistance. For instance, the recurrence score and the
HOXB13/IL17RB gene expression ratio are both significantly
elevated in ERþ IBC compared with ERþ nIBC. Several studies
have shown that elevated levels for both parameters are high-
ly predictive of endocrine therapy resistance (Dowsett et al.,
2010; Jansen et al., 2007; Ma et al., 2004; Paik et al., 2004). In
addition, application of the PAM50-algorithm (Tibshirani
et al., 2002) revealed a remarkably low frequency of Luminal
A-type samples, which are shown to be more frequently
responsive to endocrine treatment compared with their
Luminal B-type counterparts. This hypothesis is supported
by the observation that samples from tumors with a Luminal
B-phenotype frequently exhibit high Recurrence Scores (Fan
et al., 2006).
Using repetitive prediction analysis to obtain robust pre-
dictors, we identified a metagene of six genes consisting of
ABAT, ADAMDEC1, CLEC7A, ETS1, ITK and STC2 to discriminate
Figure 4 e KaplaneMeier Analyses for outcome after endocrine treatment The metagene, ABAT and STC2 as IBC/nIBC classifiers and their
relation with PFS as measure for treatment outcome in advanced disease after first-line tamoxifen (series IV and VI) and aromatase inhibitors
(series V).
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These biomarkers were each verified and demonstrated that
only the metagene and the genes ABAT and STC2 remained
predictive in the test series. The metagene is a slightly better
predictor than the single genes, however, its performance in
the other series was largely dictated by ABAT and STC2. It is
intriguing that ABAT and STC2, as 2 genes not yet linked to
inflammation, discriminate between ERþ IBC and nIBC. A
role in the inflammatory response, however, is less likely to
be established since both ABAT and STC2 are down-
regulated in IBC compared to nIBC.
Recently, both ABAT and STC2 were described in the 100
rules used in the Absolute Intrinsic Molecular Subtyping
(AIMS) (Paquet and Hallett, 2015). AIMS enables subtyping
from gene expression profile at mRNA expression levels ofan individual sample without the need of large, diverse, and
normalized datasets. These findings indicate that both genes
are highly relevant inmolecular subtyping. Moreover, themo-
lecular subtyping of breast cancer becomes more and more
important in the clinical management of patients. The results
of our study may therefore contribute with regard to endo-
crine treatment decision making.
Although our study demonstrated only that both ABAT
and STC2 are just biomarkers, literature suggests for both a
role in ER signaling. ABAT (MIM: 137150) has been identified
as a luminal-like gene with an ER-binding site within 20 kb
distance from the transcription start site (Krijgsman et al.,
2011). This gene is incorporated in Agendia’s BluePrint assay,
an 80-gene molecular subtyping profile developed in 200
breast cancer specimens and validated in four independent
Table 4eBiomarkers and published signatures in advanced disease. The metagene,ABAT and STC2were compared with the published signatures
for Recurrence Score and Genomic Grade Index (GGI) for their relationship with PFS in advanced disease after treatment with tamoxifen (series
IV and VI) or aromatase inhibitors (series V).
Univariate Bivariate (biomarker together with published signature evaluated)
Metagene score ABAT STC2
Signature N HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Series IV. Tam (N ¼ 96)
Recurrence Score
low 35 1.00 1.11 (0.99e1.24) 0.085 0.84 (0.71e0.99) 0.036 0.94 (0.82e1.09) 0.430
moderate 12 1.01 (0.49e2.08) 0.977
high 49 1.61 (1.00e2.60) 0.050
GGI 96 0.99 (0.90e1.10) 0.899 1.14 (1.03e1.26) 0.010 0.80 (0.69e0.93) 0.005 0.90 (0.78e1.03) 0.113
TAM78 62 2.34 (1.34e4.11) 0.003 1.11 (0.98e1.27) 0.102 0.86 (0.71e1.04) 0.130 0.94 (0.79e1.11) 0.455
ROR-S
low 33 1.00 1.10 (0.97e1.24) 0.141 0.85 (0.72e1.01) 0.065 0.96 (0.83e1.10) 0.534
moderate 30 1.42 (0.82e2.46) 0.216
high 33 1.93 (1.14e3.25) 0.014
ROR-P
low 23 1.00 1.13 (1.01e1.26) 0.039 0.80 (0.67e0.96) 0.018 0.91 (0.78e1.06) 0.230
moderate 37 0.93 (0.53e1.65) 0.816
high 36 1.34 (0.77e2.33) 0.307
Series V. AI (N ¼ 84)
Recurrence Score
low 18 1.00 1.23 (1.08e1.42) 0.003 0.77 (0.62e0.95) 0.013 0.79 (0.67e0.93) 0.004
moderate 7 1.85 (0.64e5.36) 0.259
high 59 2.86 (1.34e6.07) 0.006
GGI 84 3.64 (1.87e7.08) <0.001 1.19 (1.03e1.38) 0.019 0.84 (0.67e1.05) 0.124 0.84 (0.71e0.99) 0.043
TAM78 84 1.80 (1.08e3.00) 0.023 1.26 (1.11e1.44) 0.001 0.74 (0.60e0.93) 0.008 0.76 (0.65e0.88) <0.001
ROR-S
Low 24 1.00 1.19 (1.03e1.37) 0.016 0.82 (0.66e1.03) 0.087 0.83 (0.71e0.97) 0.018
moderate 31 1.20 (0.61e2.36) 0.603
high 29 3.20 (1.65e6.21) 0.001
ROR-P
low 18 1.00 1.19 (1.03e1.38) 0.017 0.80 (0.64e1.00) 0.050 0.82 (0.71e0.96) 0.015
moderate 38 1.79 (0.84e3.82) 0.132
high 28 3.94 (1.81e8.59) 0.001
Series VI. Tam (N ¼ 231), qRT-PCR
Recurrence Score
low 65 1.00 1.05 (0.99e1.11) 0.134 0.88 (0.80e0.97) 0.011 0.96 (0.90e1.02) 0.196
moderate 13 1.90 (1.00e3.60) 0.048
high 131 2.39 (1.70e3.37) <0.001
GGI 226 1.53 (1.29e1.81) <0.001 1.06 (1.01e1.12) 0.032 0.89 (0.81e0.97) 0.009 0.94 (0.89e1.01) 0.057
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ferase, an enzyme responsible for the catabolism of
gamma-aminobutyric acid (GABA), which might be involved
in the hormonal regulation and pathogenesis of breast can-
cer (Opolski et al., 2000). Moreover, comparative metabolo-
mics demonstrated alterations in glutamine and beta-
alanine metabolism along with low ABAT expression with
shortened survival in ERþ and ER breast cancer (Budczies
et al., 2013).
Bouras and colleagues have shown that STC2 (MIM: 603665)
as an estrogen responsive gene is co-expressed with ER
(Bouras et al., 2002). In fact, independent studies have indeed
shown that STC2 is a dynamic marker of estrogen-driven
pathway activation and that constitutive expression after
serum withdrawal negatively affects breast cancer cell
growth, cell viability and cell migration (Raulic et al., 2008;Urruticoechea et al., 2008)). Therefore, reduced expression of
STC2 in breast cancer cells enables survival and cell growth
in the absence of estrogen, thereby contributing to endocrine
treatment resistance. Of note, in a recent effort to redefine the
molecular portraits of IBC on an extended series of 137 sam-
ples, repressed STC2 expression levels were observed in IBC
in a molecular subtype-independent manner (Van Laere
et al., 2010). Future studies are needed to provide functional
evidence that ABAT and STC2 are mechanistically involved
in endocrine therapy response.
Based upon above considerations and findings we evalu-
ated ABAT and STC2 further in different datasets to determine
their relationship with prognosis and treatment outcome to
adjuvant and first-line endocrine therapy (i.e. tamoxifen and
aromatase inhibitors). Both biomarkers were not prognostic,
whereas only decreased levels of ABAT were associated with
Table 5e Biomarkers and clinico-pathological factors in advanced disease. This table provides the results of the uni- and multivariate Cox regression analyses for PFS performed on the advanced disease
patient series (series IVeVI). The biomarkers were separately added to the base model of clinico-pathological factors in multivariate analysis.
Clinicopathological
factors
Series IV. Tam (N ¼ 96) Series V. AI (N ¼ 84) Series VI. Tam (N ¼ 231), qRT-PCR
N Univariate (N ¼ 96) Multivariate (N ¼ 91) N Univariate (N ¼ 84) Multivariate (N ¼ 82) N Univariate (N ¼ 231) Multivariate (N ¼ 231)
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Age
<55 34 1.00 1.00 18 1.00 1.00 91 1.00 1.00
56e70 43 0.75 (0.46e1.22) 0.250 1.09 (0.43e2.79) 0.855 32 1.07 (0.56e2.05) 0.839 0.86 (0.36e2.02) 0.727 81 0.78 (0.57e1.07) 0.123 0.83 (0.53e1.31) 0.427
>70 19 0.90 (0.49e1.65) 0.742 1.21 (0.44e3.38) 0.712 34 0.75 (0.38e1.46) 0.390 0.59 (0.23e1.48) 0.260 59 0.69 (0.48e0.98) 0.038 0.69 (0.43e1.12) 0.134
Menopausal status
Premenopausal 29 1.00 1.00 7 1.00 1.00 61 1.00 1.00
Postmenopausal 67 0.81 (0.51e1.30) 0.388 0.99 (0.39e2.54) 0.988 76 0.99 (0.43e2.30) 0.978 1.29 (0.41e4.04) 0.662 170 0.80 (0.59e1.09) 0.155 1.14 (0.72e1.80) 0.586
Dominant site of relapse
Bone 41 1.00 1.00 46 1.00 1.00 120 1.00 1.00
LRR or viscera 53 0.81 (0.52e1.26) 0.345 0.78 (0.46e1.32) 0.357 38 0.79 (0.48e1.31) 0.367 0.86 (0.49e1.49) 0.586 111 0.91 (0.69e1.20) 0.518 0.93 (0.70e1.23) 0.600
Disease free interval
<1 year 17 1.00 1.00 14 1.00 1.00 65 1.00 1.00
2e3 years 24 0.43 (0.22e0.84) 0.013 0.43 (0.21e0.88) 0.021 28 0.64 (0.32e1.27) 0.204 0.84 (0.39e1.79) 0.650 100 0.58 (0.42e0.80) 0.001 0.55 (0.40e0.77) <0.001
>3 years 52 0.36 (0.20e0.64) 0.001 0.33 (0.18e0.63) 0.001 41 0.38 (0.19e0.75) 0.005 0.44 (0.21e0.91) 0.027 66 0.47 (0.32e0.68) <0.001 0.46 (0.32e0.67) <0.001
mRNA levels as continuous variable:
ESR1 96 0.84 (0.73e0.95) 0.007 0.81 (0.68e0.96) 0.016 84 0.67 (0.32e1.40) 0.285 1.03 (0.46e2.35) 0.935 231 0.91 (0.85e0.97) 0.003 0.93 (0.86e1.00) 0.037
PGR 95 0.94 (0.86e1.03) 0.217 0.99 (0.88e1.10) 0.807 84 0.55 (0.37e0.80) 0.002 0.61 (0.40e0.94) 0.026 231 0.90 (0.84e0.97) 0.004 0.92 (0.85e1.00) 0.043
HER2 96 1.05 (0.89e1.25) 0.550 1.13 (0.94e1.37) 0.198 84 1.17 (0.69e1.98) 0.563 1.40 (0.79e2.50) 0.253 231 1.13 (1.00e1.27) 0.044 1.07 (0.95e1.20) 0.279
Added to the model Added to the model Added to the model
Metagene score 96 1.29 (1.13e1.46) <0.001 1.09 (0.95e1.24) 0.210 84 1.28 (1.13e1.45) <0.001 1.24 (1.07e1.44) 0.005 231 1.09 (1.04e1.14) <0.001 1.08 (1.02e1.14) 0.009
ABAT 96 0.80 (0.69e0.94) 0.005 0.78 (0.63e0.97) 0.027 84 0.74 (0.60e0.91) 0.004 0.83 (0.65e1.05) 0.127 231 0.85 (0.80e0.92) <0.001 0.87 (0.79e0.96) 0.004
STC2 96 0.90 (0.79e1.03) 0.117 0.99 (0.83e1.18) 0.903 84 0.76 (0.66e0.88) <0.001 0.79 (0.67e0.95) 0.011 231 0.93 (0.88e0.98) 0.004 0.93 (0.87e0.99) 0.017
M
O
L
E
C
U
L
A
R
O
N
C
O
L
O
G
Y
9
(
2
0
1
5
)
1
2
1
8
e
1
2
3
3
1229
Figure 5 e ABAT and STC2 protein expression The expression of ABAT and STC2 protein was evaluated with immunohistochemistry in 110
ER-positive primary tumor specimens of advanced breast cancer patients treated with first-line tamoxifen. In Figure 5A representative samples are
shown for ABAT and STC2 staining in IBC and nIBC patients. Figure 5B demonstrates the staining categories for quantity, intensity, and IHC-
scores, and the distribution of IHC-scores for ABAT and STC2. The IHC-scores were dichotomized into positive and negative scores, identifying
77 ABAT-positive and 78 STC2-positive specimens. Both ABAT and STC2 protein expression had no relationship with progression free survival.
MO L E C U L A R O N C O L O G Y 9 ( 2 0 1 5 ) 1 2 1 8e1 2 3 31230shorter MFS after adjuvant tamoxifen. In the advanced dis-
ease setting, decreased expression of ABAT and STC2 charac-
terized patients with reduced PFS under either tamoxifen- or
AI-based endocrine therapy. Particularly in patients treated
with first-line tamoxifen these “ERþ IBC-like” predictors
were associated with sensitivity to endocrine treatment in
an independent data set profiled with an alternative technol-
ogy. The latter is important as it proves that determination of
ABAT and STC2 expression levels is also applicable with stan-
dard PCR technologies, making the “bench-to-bedside” transi-
tion more feasible. We also explored whether ABAT and STC2
protein expression might be applicable as predictive bio-
markers in immunohistochemical assays, however, our find-
ings showed no relationship with tamoxifen outcome.
Combining these biomarkers with clinico-pathological fac-
tors in multivariate analyses demonstrated that ABAT
remained significantly associated with response to tamoxifen
in two independent patient series, whereas the metagene and
STC2 was only independent within the qRT-PCR validation.
Moreover, only ABAT remained independent predictive for
tamoxifen in both patient series when combined with the
published signatures Recurrence Score and GGI. All these
multivariate analyses on different patient series summarizedindicate ABAT as a robust predictor for the response to
tamoxifen.
In conclusion, this study has identified an increased meta-
gene score and decreased expression of ABAT and STC2 in IBC,
and correlated the metagene and low expression of the genes
withpoortamoxifentreatmentoutcome intheadvancedsetting
asshownwithqRT-PCR inan independentvalidation.ABATand
STC2 protein expression were not informative with regard to
treatment outcome. Further studies on the classifier genes are
needed to elucidate the mechanism of therapy resistance.Funding
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